von Willebrand Factor and Aging

Barbara A. Konkle

doi:10.1055/s-0034-1389079

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2014; 40(06): 640-644
DOI: 10.1055/s-0034-1389079

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

von Willebrand Factor and Aging

Authors

Barbara A. Konkle

¹Puget Sound Blood Center, Seattle, Washington

²Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington

Abstract

von Willebrand factor (VWF) plays critical roles in initiating primary hemostasis and extending the half-life of coagulation factor VIII in circulation. VWF levels increase with age and elevated levels are associated with an increased risk of venous thromboembolism and cardiovascular disease (CVD). Patients with von Willebrand disease (VWD) due to a deficiency or dysfunction of VWF may have symptoms that ameliorate with aging or may have exacerbation of their disease. Bleeding sites of particular challenge in the aging patient include gastrointestinal bleeding and hematuria. Some medications used to treat VWD should be used with special precaution in older patients, including desmopressin and VWF-containing factor concentrates. Patients with VWD may have some protection from CVD, but in those patients who develop CVD, management is very challenging, given the role of antiplatelet therapy as the mainstay of treatment.

Keywords

von Willebrand factor - von Willebrand disease - factor VIII - hemorrhage - thrombosis - aging

Full Text

References

References
1 Konkle BA, Rick ME, Von Willebrand Disease. . In: Kitchens CS, Kessler CM, Konkle BA. , eds. Consultative Hemostasis and Thrombosis, 3 ^rd Edition. Philadelphia: Elsevier Saunders; 2013: 90-102
2 James PD, Lillicrap D. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. Am J Hematol 2012; 87 (Suppl. 01) S4-S11
3 Davies JA, Hathaway LS, Collins PW, Bowen DJ. von Willebrand factor: demographics of plasma protein level in a large blood donor cohort from South Wales in the United Kingdom. Haemophilia 2012; 18 (3) e79-e81
4 Blombäck M, Konkle BA, Manco-Johnson MJ, Bremme K, Hellgren M, Kaaja R ; ISTH SSC Subcommittee on Women's Health Issues. Preanalytical conditions that affect coagulation testing, including hormonal status and therapy. J Thromb Haemost 2007; 5 (4) 855-858
5 Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999; 82 (5) 1456-1461
6 Bladbjerg EM, de Maat MPM, Christensen K, Bathum L, Jespersen J, Hjelmborg J. Genetic influence on thrombotic risk markers in the elderly—a Danish twin study. J Thromb Haemost 2006; 4 (3) 599-607
7 McGill SN, Ahmed NA, Christou NV. Increased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activation. Crit Care Med 1998; 26 (2) 296-300
8 Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005; 42 (1) 49-55
9 Ocak G, Vossen CY, Verduijn M , et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost 2013; 11 (1) 116-123
10 van Loon JE, Kavousi M, Leebeek FW , et al. von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population. J Thromb Haemost 2012; 10 (7) 1262-1269
11 van Schie MC, van Loon JE, de Maat MPM, Leebeek FWG. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost 2011; 9 (5) 899-908
12 Campos M, Buchanan A, Yu F , et al. Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study. Blood 2012; 119 (8) 1929-1934
13 Fuster W, Bowie EJ, Lewis JC, Fass DN, Owen Jr CA, Brown AL. Resistance to arteriosclerosis in pigs with von Willebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest 1978; 61 (3) 722-730
14 Srámek A, Bucciarelli P, Federici AB , et al. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 2004; 109 (6) 740-744
15 Sanders YV, Eikenboom J, de Wee EM , et al; WiN Study Group. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 2013; 11 (5) 845-854
16 Smith NL, Rice KM, Bovill EG , et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood 2011; 117 (22) 6007-6011
17 van Schie MC, de Maat MPM, Isaacs A , et al. Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood 2011; 117 (4) 1393-1399
18 Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013; 122 (23) 3735-3740
19 Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J Thromb Haemost 2006; 4 (9) 1925-1927
20 Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev 2007; 21 (2) 89-97
21 Messing EM, Young TB, Hunt VB , et al. Home screening for hematuria: results of a multiclinic study. J Urol 1992; 148 (2 Pt 1) 289-292
22 Quon DV, Konkle BA. How we treat: haematuria in adults with haemophilia. Haemophilia 2010; 16 (4) 683-685
23 Philipp CS, Faiz A, Dowling N , et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol 2005; 105 (1) 61-66
24 Kouides PA, Byams VR, Philipp CS , et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145 (2) 212-220
25 Huq FY, Al-Haderi M, Kadir RA. The outcome of endometrial ablation in women with inherited bleeding disorders. Haemophilia 2012; 18 (3) 413-420
26 Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 2012; 19 (1) 109-117
27 Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; (4) CD001500
28 Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351 (7) 683-694
29 Suryanarayan D, Goodyear D, Poon M-C. DDAVP use and cardiovascular outcomes in patients with bleeding disorders undergoing invasive procedures (abstract). J Thromb Haemost 2013; (Suppl. 02) (11): 947
30 Konkle BA. von Willebrand disease: treatment with or without factor VIII?. J Thromb Haemost 2007; 5 (6) 1113-1114
31 Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88 (3) 378-379